Long-acting Etonogestrel Microspheres

Description: Orbis Biosciences is developing a 6-month injectable microsphere formulation containing etonogestrel using Orbis Biosciences' patented Precision Particle Fabrication (PPF) technology for achieving uniform particle size.

Product Details

User: Female

Hormonal: Yes

Delivery Method: Injectable, Subdermal

Duration Type: Long-acting

Duration: 6 months

Regimen:
  • single injection

Active Pharmaceutical Ingredient (API):
  • etonogestrel

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: Orbis Biosciences

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Pre-clinical

Began discovery in: 2013

Active Development: Yes

Additional Information

References:

Vertical Tabs

Print